Skip to main content
OpenTrials

Clinical trial condition

Relapsed/Refractory Multiple Myeloma

Explore clinical trials studying Relapsed/Refractory Multiple Myeloma. Study availability and eligibility vary by location and protocol.

51 public trials 22 recruiting studies
Refine in advanced search Browse all conditions

Relapsed/Refractory Multiple Myeloma trial results

Enrolling by invitation

Long-Term Follow-up Study

NCT05332054

Conditions
B Cell Lymphoma, B-cell Non-Hodgkin's Lymphoma, Blood Protein Disorders, +29 more
Locations
  • University of Alabama Birmingham, Alabama, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Honor Health Research Institute Scottsdale, Arizona, United States
  • University of California Irvine Irvine, California, United States
View all 31 locations
View Trial Details
Active, not recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05259839

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • University of Arkansas for Medical Sciences /ID# 243096 Little Rock, Arkansas, United States
  • Sylvester Comprehensive Cancer Center /ID# 243673 Miami, Florida, United States
  • Moffitt Cancer Center /ID# 243437 Tampa, Florida, United States
  • University of Maryland, Baltimore /ID# 243679 Baltimore, Maryland, United States
View all 49 locations
View Trial Details
Active, not recruiting

A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

NCT05704049

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Investigational Site Number : 0360002 Wollongong, New South Wales, Australia
  • Investigational Site Number : 0360001 Melbourne, Victoria, Australia
  • Hospital Mae de Deus Site Number : 0760002 Porto Alegre, Rio Grande do Sul, Brazil
  • Clinica São Germano- Site Number : 0760003 São Paulo, Brazil
View all 23 locations
View Trial Details
Active, not recruiting

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

NCT05308654

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Stanford University School of Med /ID# 242809 Stanford, California, United States
  • Sylvester Comprehensive Cancer Center /ID# 243417 Miami, Florida, United States
  • Tulane University School of Medicine /ID# 244854 New Orleans, Louisiana, United States
  • American Oncology Partners of Maryland /ID# 244858 Bethesda, Maryland, United States
View all 21 locations
View Trial Details
Active, not recruiting

A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan

NCT05286229

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • National Cancer Center Hospital East /ID# 240943 Kashiwa-shi, Chiba, Japan
  • Hokkaido University Hospital /ID# 242672 Sapporo, Hokkaido, Japan
  • Kanazawa University Hospital /ID# 240948 Kanazawa, Ishikawa-ken, Japan
  • Duplicate_Okayama Medical Center /ID# 240949 Okayama, Okayama-ken, Japan
View Trial Details
Completed

BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma

NCT05376345

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Beijing Boren Hospital Beijing, Beijing Municipality, China
  • Zhejiang Provincial People's Hospital Hangzhou, Zhejiang, China
  • Shanghai Changzheng Hospital Shanghai, China
  • Shanghai Fourth People's Hospital Affiliated to Tongji University Shanghai, China
View Trial Details
Completed

Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

NCT04093596

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • City of Hope Duarte, California, United States
  • Stanford Cancer Institute Palo Alto, California, United States
  • Sarah Cannon/Colorado Blood Cancer Institute Denver, Colorado, United States
View Trial Details
Completed

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

NCT03309111

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States
  • Mayo Clinic Cancer Center (MCCC) - Rochester Rochester, Minnesota, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
View all 20 locations
View Trial Details

Related conditions